


3rd Annual Global Summit on

GENITOURINARY


MALIGNANCIES

OCTOBER 10-13, 2019

BANFF | CANADA



GENITOURINARY MALIGNANCIES



OCTOBER 10-13, 2019

BANFF | CANADA

AGENDA

Thursday, October 10, 2019

5:45 PM Welcome and Introductions

KEYNOTE ADDRESS

6:00 PM GU Malignancies: Perspectives and a Peer Into the Future

SETTING THE STAGE

6:30 PM What are the Practice Changes in 2019 for Advanced Prostate Cancer?

6:45 PM What are the Practice Changes in 2019 for Metastatic RCC?

7:00 PM What are the Practice Changes in 2019 for Bladder Cancer?

7:15 PM Moving Forward with Immunotherapy in GU Malignancies

7:30 PM The Era of Personalized Therapy for GU Tumors

7:45 PM DISCUSSION

8:00 PM ADJOURN TO WELCOME RECEPTION

Friday, October 11, 2019

6:00 AM BREAKFAST

ADVANCES IN IMAGING AND DIAGNOSIS

7:00 AM Blue Light Flexible Cystoscopy with Hexaminolevulinate for Surveillance of Bladder Cancer

7:15 AM PET Imaging in Prostate Cancer

7:30 AM Challenges with RCC Type 1 and Type 2 Pathology Diagnosis

7:45 AM Subtyping RCC on Imaging - The Role of Radiologist

8:00 AM Modeling Cost Effectiveness of Biomarker Based Approaches to Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer

8:15 AM Biotech Showcase

8:30 AM DISCUSSION

THE ROLE OF SURGERY IN GU MALIGNANCIES

9:00 Optimal Timing for Radical Cystectomy After Neoadjuvant Chemotherapy

9:15 Radical Prostatectomy in Metastatic Disease

9:30 Discussion

10:00 BREAK

IMMUNOTHERAPY IN GU MALIGNANCIES

10:15 AM Maximizing Clinical Response to Immune Checkpoint Therapy in GU Malignancies

10:30 AM Current Data and Future Trials for PD-1/PD-L1 Inhibitors for Bladder Cancer

10:45 AM Is There a Future for Immunotherapy in Prostate Cancer?

11:15 AM Biotech Showcase

11:30 AM DISCUSSION AND CASE STUDIES

12:00 PM ADJOURN

CURRENT UNDERSTANDING OF TKI IN RCC

5:00 PM How do we Optimize the Effectiveness of VEGF Inhibitors?

5:15 PM The Role of Sequencing in TKIs

5:30 PM DISCUSSION

THE SPECTRUM OF METASTATIC DISEASE IN PROSTATE CANCER

5:45 PM Management of Metastatic Castrate-sensitive Prostate Cancer

6:00 PM Does Treating the Primary Make a Difference in Metastatic Disease?

6:15 PM DISCUSSION

LEARNING FROM GENOMICS AND BIOMARKERS

6:30 PM Emerging Biomarkers and Imaging Tests to Improve Prostate Cancer Diagnostics

6:45 PM Genetic Heterogeneity in Kidney Cancer

7:00 PM Genomic Classification in Localized Disease: How can it Improve Outcomes?


7:15 PM Molecular Landscape of non-Muscle Invasive Versus Muscle Invasive Bladder Cancer

7:30 PM Utilizing Genomics for the Selection of Systemic Therapy

7:45 PM DISCUSSION

8:15 PM ADJOURN

GENITOURINARY MALIGNANCIES



OCTOBER 10-13, 2019

BANFF | CANADA

AGENDA

Saturday, October 12, 2019

6:00 AM BREAKFAST

TARGETED THERAPY IN BLADDER CANCER

- 7:00 AM Targeting FGFR and mTOR in Bladder Cancer
- 7:15 AM Targeting DNA Repair Genes in Bladder Cancer
- 7:30 AM Taking Advantage of Nectin-4 Expression in Bladder Cancer with ADCs
- 7:45 AM Updates in Management of Urothelial Cancer
- 8:00 AM DISCUSSION

BLADDER PRESERVATION THERAPY

- 8:15 AM Match Pair Analysis of Cystectomy Compared to Tri-Modality Therapy
- 8:30 AM Curative Treatments of Invasive Bladder Cancer Using Combined Modality Therapy
- 9:00 AM Combining Immunotherapy and Radiation Therapy in Bladder Cancer
- 9:15 AM DISCUSSION

TARGETING AR IN CRPC: A MAJOR THERAPEUTIC CHALLENGE

- 9:30 AM AR Agents in non-Metastatic CRPC
- 9:45 AM Biologic Rationale for Next-generation AR Inhibitors
- 10:00 AM Approaches to Block Persistent AR Function in Metastatic CRPC
- 10:15 AM An Androgen Receptor PROTAC Degradar for Prostate Cancer
- 10:30 AM DISCUSSION
- 10:45 AM BREAK

MOVING BEYOND HORMONE RECEPTORS IN PROSTATE CANCER

- 10:55 AM PARP inhibitors in Prostate Cancer
- 11:10 AM Alterations in AR Signaling in Prostate Cancer Development and Progression
- 11:25 AM CDK4/6 Inhibition as Novel Therapeutic Strategy for Metastatic Prostate Cancer
- 11:40 AM Biotech Showcase
- 11:55 AM DISCUSSION AND CASE STUDIES
- 12:30 PM ADJOURN

QUALITY OF LIFE AND OUTCOME CONSIDERATIONS FOR GU MALIGNANCIES

- 5:00 PM How can PRO Drive Drug Development and Standards of Care?
- 5:15 PM Emerging Quality of Life Trends with Early Use of Novel Antiandrogen Therapies in Advanced Prostate Cancer
- 5:30 PM Improving Real World Outcomes in Bladder Cancer
- 5:45 PM Integrating Lifestyle Changes and Exercise into Prostate Cancer Care
- 6:00 PM DISCUSSION

COMBINATION APPROACHES FOR IMMUNOTHERAPY

- 6:15 PM Combination Therapy Targeting CTLA-4 and PD-1/PD-L1: Risks and Benefits for RCC
- 6:30 PM Immunotherapy Combination Approaches with Chemotherapy and Targeted Therapies in Bladder Cancer
- 6:45 PM Biotech Showcase
- 7:00 PM Biotech Showcase
- 7:15 PM DISCUSSION

PRACTICAL CONSIDERATION FOR IMMUNOTHERAPY

- 7:30 PM Managing Immunotherapy Toxicity in Bladder Cancer
- 7:45 PM Treatment After Checkpoint Therapy, What do we do Post Immunotherapy?
- 8:00 PM DISCUSSION
- 8:15 PM ADJOURN

Sunday, October 13, 2019

6:00 AM BREAKFAST

ORAL ABSTRACTS

- 7:00 AM Oral Abstract 1
- 7:15 AM Oral Abstract 2
- 7:30 AM Oral Abstract 3
- 7:45 AM Oral Abstract 4
- 8:00 AM Oral Abstract 5
- 8:15 AM Oral Abstract 6
- 8:30 AM MEETING CONCLUDES

3rd Annual Global Summit on

GENITOURINARY

MALIGNANCIES

